Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

This guidance provides a data-supported approach to the diagnosis, staging, and treatment
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

These recommendations provide a data-supported approach to the diagnosis, staging and
treatment of patients diagnosed with hepatocellular carcinoma (HCC). They are based on …

The construct validity of a quantitative work productivity and activity impairment (WPAI)
measure of health outcomes was tested for use in clinical trials, along with its reproducibility …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many
patients have concurrent liver disease, which can confound the assessment of clinical …

BACKGROUND Cost-effectiveness analysis involves the comparison of the incremental cost-
effectiveness ratio of a new technology, which is more costly than existing alternatives, with …

A study of the quality of life and cost-utility of renal transplantation. The objective of this study
was to assess the cost-utility of renal transplantation compared with dialysis. To accomplish …